Folgen
Giulio Draetta
Giulio Draetta
The University of Texas MD Anderson Cancer Center
Bestätigte E-Mail-Adresse bei mdanderson.org
Titel
Zitiert von
Zitiert von
Jahr
Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27
M Pagano, SW Tam, AM Theodoras, P Beer-Romero, G Del Sal, V Chau, ...
Science 269 (5224), 682-685, 1995
23141995
Cyclin D1 is a nuclear protein required for cell cycle progression in G1.
V Baldin, J Lukas, MJ Marcote, M Pagano, G Draetta
Genes & development 7 (5), 812-821, 1993
21391993
Cyclin A is required at two points in the human cell cycle.
M Pagano, R Pepperkok, F Verde, W Ansorge, G Draetta
The EMBO journal 11 (3), 961-971, 1992
17971992
Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas
M Loda, B Cukor, SW Tam, P Lavin, M Fiorentinc, GF Draetta, JM Jessup, ...
Nature medicine 3 (2), 231-234, 1997
14051997
Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function
A Viale, P Pettazzoni, CA Lyssiotis, H Ying, N Sánchez, M Marchesini, ...
Nature 514 (7524), 628-632, 2014
12492014
Activation of cdc2 protein kinase during mitosis in human cells: cell cycle-dependent phosphorylation and subunit rearrangement
G Draetta, D Beach
Cell 54 (1), 17-26, 1988
9611988
Phosphorylation and activation of human cdc25‐C by cdc2‐‐cyclin B and its involvement in the self‐amplification of MPF at mitosis.
I Hoffmann, PR Clarke, MJ Marcote, E Karsenti, G Draetta
The EMBO journal 12 (1), 53-63, 1993
8931993
Cdc2 protein kinase is complexed with both cyclin A and B: evidence for proteolytic inactivation of MPF
G Draetta, F Luca, J Westendorf, L Brizuela, J Ruderman, D Beach
Cell 56 (5), 829-838, 1989
8291989
FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to γ-secretase inhibitors
J O'Neil, J Grim, P Strack, S Rao, D Tibbitts, C Winter, J Hardwick, ...
The Journal of experimental medicine 204 (8), 1813-1824, 2007
8072007
An inhibitor of oxidative phosphorylation exploits cancer vulnerability
JR Molina, Y Sun, M Protopopova, S Gera, M Bandi, C Bristow, T McAfoos, ...
Nature medicine 24 (7), 1036-1046, 2018
7952018
Ubiquitination of p27 is regulated by Cdk-dependent phosphorylation and trimeric complex formation
A Montagnoli, F Fiore, E Eytan, AC Carrano, GF Draetta, A Hershko, ...
Genes & development 13 (9), 1181-1189, 1999
7521999
Yap1 activation enables bypass of oncogenic Kras addiction in pancreatic cancer
A Kapoor, W Yao, H Ying, S Hua, A Liewen, Q Wang, Y Zhong, CJ Wu, ...
Cell 158 (1), 185-197, 2014
7482014
CDC25 phosphatases as potential human oncogenes
K Galaktionov, AK Lee, J Eckstein, G Draetta, J Meckler, M Loda, D Beach
Science 269 (5230), 1575-1577, 1995
6751995
Activation of the phosphatase activity of human cdc25A by a cdk2‐cyclin E dependent phosphorylation at the G1/S transition.
I Hoffmann, G Draetta, E Karsenti
The EMBO journal 13 (18), 4302-4310, 1994
6571994
Regulating mammalian checkpoints through Cdc25 inactivation
M Donzelli, GF Draetta
EMBO reports 4 (7), 671-677, 2003
6462003
Genetics and biology of pancreatic ductal adenocarcinoma
H Ying, P Dey, W Yao, AC Kimmelman, GF Draetta, A Maitra, RA DePinho
Genes & development 30 (4), 355-385, 2016
6022016
SCFFbxl3 controls the oscillation of the circadian clock by directing the degradation of cryptochrome proteins
L Busino, F Bassermann, A Maiolica, C Lee, PM Nolan, SIH Godinho, ...
science 316 (5826), 900-904, 2007
6022007
Calcineurin
CB Klee, GF Draetta, MJ Hubbard
Advances in enzymology and related areas of molecular biology 61, 149-200, 1988
5801988
Degradation of Cdc25A by β-TrCP during S phase and in response to DNA damage
L Busino, M Donzelli, M Chiesa, D Guardavaccaro, D Ganoth, ...
Nature 426 (6962), 87-91, 2003
5542003
Reversible tyrosine phosphorylation of cdc2: dephosphorylation accompanies activation during entry into mitosis
AO Morla, G Draetta, D Beach, JYJ Wang
Cell 58 (1), 193-203, 1989
5511989
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20